You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mirvetuximab soravtansine

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Endometrial Cancer Trial in Boston, Worcester (Pembrolizumab, IMGN853)

Recruiting
  • Endometrial Cancer
  • Boston, Massachusetts
  • +2 more
Oct 24, 2022

Endometrial Cancer Trial in New Haven (IMGN853)

Recruiting
  • Endometrial Cancer
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 10, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer Trial in Birmingham (mirvetuximab soravtansine (MIRV; IMGN853))

Recruiting
  • Ovarian Cancer
  • +2 more
  • mirvetuximab soravtansine (MIRV; IMGN853)
  • Birmingham, Alabama
    University of Alabama at Birmingham Womens & Infants Center
Jun 30, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • Pegylated Liposomal Doxorubicin + SL-172154
  • Mirvetuximab + SL-172154
  • (no location specified)
Jul 29, 2022

Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine,

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • +4 more
  • Birmingham, Alabama
  • +15 more
Dec 13, 2021

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • Anchorage, Alaska
  • +55 more
Jul 25, 2022

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab Soravtansine)

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • Phoenix, Arizona
  • +88 more
Jan 19, 2023

Tumors Trial in Canada, United States (Mirvetuximab soravtansine)

Completed
Has Results
  • Tumors
  • Mirvetuximab soravtansine
  • Fairway, Kansas
  • +11 more
Jan 27, 2021

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Completed
Has Results
  • Anatomic Stage II Breast Cancer AJCC v8
  • +20 more
  • Mirvetuximab Soravtansine
  • Houston, Texas
    M D Anderson Cancer Center
Nov 18, 2020

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in China (Mirvetuximab Soravtansine)

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • Bengbu, Anhui, China
  • +27 more
Nov 14, 2022

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab Soravtansine, Paclitaxel,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • +3 more
  • Birmingham, Alabama
  • +207 more
Oct 28, 2022

Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in Oklahoma City (Mirvetuximab

Withdrawn
  • Endometrial Cancer
  • +3 more
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Jun 25, 2019

Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine,

Completed
Has Results
  • Epithelial Ovarian Cancer
  • +3 more
  • Mirvetuximab soravtansine
  • +3 more
  • Birmingham, Alabama
  • +130 more
Sep 24, 2020

Breast Cancer Triple Negative Trial in Durham (Mirvetuximab Soravtansine (IMGN853))

Withdrawn
  • Breast Cancer Triple Negative
  • Mirvetuximab Soravtansine (IMGN853)
  • Durham, North Carolina
    Duke University Medical Center
Jul 2, 2018